Product Description
NNC0165-1875 is being developed by Novo Nordisk for the treatment of patients with obesity. It is a novel analogue of the appetite-regulating hormone, PYY, intended for once-weekly treatment. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03707990?term=NNC0165-1875&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: Europe
Company CEO: Lars Fruergaard Jorgensen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Obesity
Phase 1: Overweight|Obesity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03707990 |
NN9775-4398 | P1 |
Completed |
Obesity|Overweight |
2019-08-13 |
12% |
2019-09-04 |
Primary Completion Date|Study Completion Date |
NCT04969939 |
NN9775-4708 | P2 |
Completed |
Obesity |
2022-12-06 |
50% |
2023-12-08 |
Patient Enrollment|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/18/2023 |
News Article |
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH |